LL-37 and Lyme disease: peptide hype vs. actual evidence

What did @coachcam.peps3 actually say?

The creator argues that LL-37, the only human cathelicidin antimicrobial peptide, is a natural weapon against Lyme disease because it can disrupt the biofilms that protect Borrelia burgdorferi from antibiotics. He also claims that Borrelia actively downregulates LL-37 production, that Lyme patients have measurably lower LL-37 levels, and that gut dysbiosis from antibiotic treatment further suppresses this peptide. He closes with a recommendation to maintain adequate vitamin D, which he says upregulates LL-37.

The core argument is that a suppressed innate immune peptide leaves Lyme patients fighting an uphill battle, and that LL-37's anti-biofilm properties make it uniquely relevant to treatment-resistant cases. He is careful to frame everything as educational, not medical advice, which is worth noting. The framing is provocative but not entirely without basis.

Does the science back this up?

Partially, yes. LL-37's anti-biofilm activity and its role in innate immunity are well-documented. The claim that Borrelia suppresses host LL-37 has some support, but the evidence is thinner than the confident delivery suggests.

LL-37 does disrupt bacterial biofilms by inserting into lipid membranes and destabilizing their structure. This has been demonstrated against a range of pathogens. Dürr, Sudheendra, and Ramamoorthy (2006, Biochimica et Biophysica Acta) described the membrane-disrupting mechanism in detail. Regarding Lyme specifically, Horowitz and Freeman (2019, Antibiotics) published work on biofilm-forming Borrelia and multi-modal treatment approaches, though LL-37 was not the focus. The claim that Borrelia downregulates LL-37 is referenced in some immunopathology literature, but robust peer-reviewed clinical trials demonstrating measurably lower LL-37 in Lyme patients as a consistent finding are limited. The vitamin D to LL-37 upregulation link is legitimate: Liu et al. (2006, Science) showed vitamin D receptor activation induces cathelicidin expression in human cells.

What did they get wrong (or right)?

The creator gets the biology mostly right but oversells the clinical application significantly. Calling LL-37 something that "mops the floor" with Lyme disease implies a therapeutic efficacy that has not been demonstrated in humans with Lyme disease. That is a meaningful gap.

The bacterium's name is mispronounced and slightly mangled throughout as "Boryella bor d'erfrite" rather than Borrelia burgdorferi. That is cosmetic, not scientific. More substantively, the co-infection "Babzio" is Babesia, a protozoan parasite, not a bacterium. Calling it something that "attacks your red blood cells" is accurate, but categorizing it alongside bacterial co-infections without noting it is a parasite matters if someone is trying to understand treatment implications. Antiprotozoals, not just antibiotics, are used for Babesia.

The gut dysbiosis point is reasonable and underappreciated. Antibiotic-driven microbiome disruption likely does affect epithelial LL-37 production indirectly, though direct causal data in Lyme patients is sparse. He is connecting dots that are plausible but not yet fully drawn in the literature. Credit where it is due: the vitamin D recommendation is one of the more evidence-supported things in the video.

What should you actually know?

LL-37 is a real, well-studied antimicrobial peptide. Its anti-biofilm properties are legitimate science. But there is a wide canyon between "LL-37 disrupts biofilms in lab settings" and "LL-37 treats Lyme disease." No clinical trials have tested exogenous LL-37 peptide administration in Lyme disease patients. The research base here is mostly preclinical and mechanistic.

Chronic Lyme disease, sometimes called post-treatment Lyme disease syndrome, remains genuinely contested in medicine. The Infectious Diseases Society of America and the International Lyme and Associated Diseases Society have conflicting guidelines. Biofilm-forming Borrelia is a real area of research, but it is not yet a clinically actionable target with an approved or validated therapy. Anyone considering peptide interventions for Lyme should be working with an infectious disease specialist, not a TikTok classroom. The vitamin D point is the most actionable and least controversial takeaway from this video, and it gets buried at the end.

• LL-37 is produced by neutrophils, macrophages, keratinocytes, and gut epithelial cells.
• Vitamin D receptor activation genuinely upregulates cathelicidin expression in human tissue.
• Exogenous LL-37 as a peptide therapy for Lyme disease has no human clinical trial data to date.
• Babesia is a protozoan, not a bacterium, and requires different treatment than bacterial Lyme co-infections.